LYCOS RETRIEVER 
Wyeth: Companies
built 787 days ago
Wyeth has raised discovery productivity by 500 percent, preclinical productivity by 600 percent, case report forms (CRFs) processed by 300 percent. The company is enrolling 100 percent, as in all of its planned patients, vs. just 60 percent a year earlier.
Source:
Wyeth has had its own problems with FDA rules governing advertising. In a letter from FDA dated January 11, 1999, the FDA said that promotional materials for Premarin were "false or misleading, and promote Premarin for unapproved uses." One year earlier, the company had received a letter saying that a television advertisement for Premarin was "false or misleading."
Source:
Wyeth Consumer Healthcare (formerly Whitehall-Robins Consumer Healthcare) operates in over 65 countries. The division had sales of $2.5 billion in 2004 and is the fifth largest over-the-counter health products company in the world.
Source:
Building on the success of Zosyn, Wyeth submitted a global registration dossier for the investigational antibiotic TYGACIL (tigecycline) in the fourth quarter. On January 28, 2005, Wyeth announced that the FDA granted priority review status to the Company's New Drug Application (NDA) for Tygacil. A
Source:
In 1994 Wyeth acquired American Cyanamid and its subsidiary Lederle Laboratories. This acquisition brought the Lederle Praxis vaccines, new research and development capacity, and Centrum, the leading US multivitamin. Wyeth's sales topped $13 billion in 1995; two years later, Premarin became the company's first brand to reach $1 billion in sales.
Source:
Wyeth officials said they could not comment directly on the lawsuits. A company expert on hormone replacement therapy said the Women's Health Initiative data are still being analyzed, and some of the earlier risk findings have turned out not to be statistically significant. The treatment can vary from woman to woman depending on her particular needs and other health problems.
Source:
MORE ABOUT
Companies